Introduction: As the first monoclonal antibody to have been launched for a cancer indication, Herceptin demands attention. Because of the survival advantage it brings, it has been heralded as a breakthrough. However, it is still not used in every suitable breast cancer patient.
Scope: - Investigation of physician opinion to identify the barriers to the prescription of Herceptin
- Discussion of effective strategies to overcome the barriers to the prescription of Herceptin
Report Highlights: Herceptin offers significant improvements in survival rates, but is not always being prescribed to all appropriate patients.
Product usage varies from country to country - reimbursement policies and company positioning within each geographic market impact uptake.
Reasons to Purchase: - Plan new drug development to meet patient management requirements
- Explore the reasons, rational and emotional, behind cancer specialists' decisions
- Predict future trends and perception in the treatment of breast cancer patients
